vs
阿拉斯加航空集团（ALK）与梯瓦制药（TEVA）财务数据对比。点击上方公司名可切换其他公司
梯瓦制药的季度营收约是阿拉斯加航空集团的1.4倍（$4.7B vs $3.3B），梯瓦制药净利率更高（10.2% vs -5.8%，领先16.1%），梯瓦制药同比增速更快（11.4% vs 5.2%），过去两年梯瓦制药的营收复合增速更高（11.1% vs 6.7%）
阿拉斯加航空集团是总部位于美国华盛顿州西塔科的航空控股企业，旗下拥有阿拉斯加航空、夏威夷航空两家干线航司，以及区域航司地平线航空，阿拉斯加航空还全资控股飞机地面服务提供商麦吉航空服务。
梯瓦制药工业有限公司是以色列跨国制药企业，核心业务聚焦仿制药研发生产，同时布局品牌药、药用活性成分（API）业务，也小范围开展合同生产服务及对外授权合作相关业务。
ALK vs TEVA — 直观对比
营收规模更大
TEVA
是对方的1.4倍
$3.3B
营收增速更快
TEVA
高出6.2%
5.2%
净利率更高
TEVA
高出16.1%
-5.8%
两年增速更快
TEVA
近两年复合增速
6.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $3.3B | $4.7B |
| 净利润 | $-193.0M | $481.0M |
| 毛利率 | — | 56.4% |
| 营业利润率 | — | 6.4% |
| 净利率 | -5.8% | 10.2% |
| 营收同比 | 5.2% | 11.4% |
| 净利润同比 | -16.3% | 321.7% |
| 每股收益（稀释后） | $-1.69 | $0.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALKTEVA
| Q1 26 | $3.3B | — | ||
| Q4 25 | $3.6B | $4.7B | ||
| Q3 25 | $3.8B | $4.5B | ||
| Q2 25 | $3.7B | $4.2B | ||
| Q1 25 | $3.1B | $3.9B | ||
| Q4 24 | $3.5B | $4.2B | ||
| Q3 24 | $3.1B | $4.3B | ||
| Q2 24 | $2.9B | $4.2B |
净利润ALKTEVA
| Q1 26 | $-193.0M | — | ||
| Q4 25 | $21.0M | $481.0M | ||
| Q3 25 | $73.0M | $433.0M | ||
| Q2 25 | $172.0M | $282.0M | ||
| Q1 25 | $-166.0M | $214.0M | ||
| Q4 24 | $71.0M | $-217.0M | ||
| Q3 24 | $236.0M | $-437.0M | ||
| Q2 24 | $220.0M | $-846.0M |
毛利率ALKTEVA
| Q1 26 | — | — | ||
| Q4 25 | — | 56.4% | ||
| Q3 25 | — | 51.4% | ||
| Q2 25 | — | 50.3% | ||
| Q1 25 | — | 48.2% | ||
| Q4 24 | — | 50.2% | ||
| Q3 24 | — | 49.6% | ||
| Q2 24 | — | 48.6% |
营业利润率ALKTEVA
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 6.4% | ||
| Q3 25 | 3.9% | 19.7% | ||
| Q2 25 | 7.5% | 10.9% | ||
| Q1 25 | -6.3% | 13.3% | ||
| Q4 24 | 2.1% | -0.7% | ||
| Q3 24 | 11.1% | -1.2% | ||
| Q2 24 | 11.1% | -0.1% |
净利率ALKTEVA
| Q1 26 | -5.8% | — | ||
| Q4 25 | 0.6% | 10.2% | ||
| Q3 25 | 1.9% | 9.7% | ||
| Q2 25 | 4.6% | 6.8% | ||
| Q1 25 | -5.3% | 5.5% | ||
| Q4 24 | 2.0% | -5.1% | ||
| Q3 24 | 7.7% | -10.1% | ||
| Q2 24 | 7.6% | -20.3% |
每股收益（稀释后）ALKTEVA
| Q1 26 | $-1.69 | — | ||
| Q4 25 | $0.14 | $0.42 | ||
| Q3 25 | $0.62 | $0.37 | ||
| Q2 25 | $1.42 | $0.24 | ||
| Q1 25 | $-1.35 | $0.18 | ||
| Q4 24 | $0.58 | $-0.19 | ||
| Q3 24 | $1.84 | $-0.39 | ||
| Q2 24 | $1.71 | $-0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $451.0M | $3.6B |
| 总债务越低越好 | $5.3B | — |
| 股东权益账面价值 | $3.7B | $7.9B |
| 总资产 | $20.3B | $40.7B |
| 负债/权益比越低杠杆越低 | 1.43× | — |
8季度趋势，按日历期对齐
现金及短期投资ALKTEVA
| Q1 26 | $451.0M | — | ||
| Q4 25 | $627.0M | $3.6B | ||
| Q3 25 | $2.3B | $2.2B | ||
| Q2 25 | $2.1B | $2.2B | ||
| Q1 25 | $2.5B | $1.7B | ||
| Q4 24 | $2.5B | $3.3B | ||
| Q3 24 | $2.5B | $3.3B | ||
| Q2 24 | $2.5B | $2.3B |
总债务ALKTEVA
| Q1 26 | $5.3B | — | ||
| Q4 25 | $4.8B | — | ||
| Q3 25 | $5.0B | — | ||
| Q2 25 | $4.9B | — | ||
| Q1 25 | $4.8B | — | ||
| Q4 24 | $4.5B | — | ||
| Q3 24 | $4.6B | — | ||
| Q2 24 | $2.7B | — |
股东权益ALKTEVA
| Q1 26 | $3.7B | — | ||
| Q4 25 | $4.1B | $7.9B | ||
| Q3 25 | $4.0B | $7.3B | ||
| Q2 25 | $3.9B | $6.8B | ||
| Q1 25 | $4.1B | $6.3B | ||
| Q4 24 | $4.4B | $5.4B | ||
| Q3 24 | $4.5B | $6.1B | ||
| Q2 24 | $4.2B | $6.4B |
总资产ALKTEVA
| Q1 26 | $20.3B | — | ||
| Q4 25 | $20.4B | $40.7B | ||
| Q3 25 | $20.0B | $39.9B | ||
| Q2 25 | $19.9B | $40.1B | ||
| Q1 25 | $19.8B | $38.4B | ||
| Q4 24 | $19.8B | $39.3B | ||
| Q3 24 | $19.6B | $41.8B | ||
| Q2 24 | $15.3B | $41.3B |
负债/权益比ALKTEVA
| Q1 26 | 1.43× | — | ||
| Q4 25 | 1.17× | — | ||
| Q3 25 | 1.24× | — | ||
| Q2 25 | 1.26× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.04× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 0.63× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $229.0M | $1.2B |
| 自由现金流经营现金流 - 资本支出 | — | $1.0B |
| 自由现金流率自由现金流/营收 | — | 21.6% |
| 资本支出强度资本支出/营收 | 10.2% | 3.0% |
| 现金转化率经营现金流/净利润 | — | 2.41× |
| 过去12个月自由现金流最近4个季度 | — | $1.1B |
8季度趋势，按日历期对齐
经营现金流ALKTEVA
| Q1 26 | $229.0M | — | ||
| Q4 25 | $185.0M | $1.2B | ||
| Q3 25 | $229.0M | $369.0M | ||
| Q2 25 | $376.0M | $227.0M | ||
| Q1 25 | $459.0M | $-105.0M | ||
| Q4 24 | $274.0M | $575.0M | ||
| Q3 24 | $318.0M | $693.0M | ||
| Q2 24 | $580.0M | $103.0M |
自由现金流ALKTEVA
| Q1 26 | — | — | ||
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $233.0M | ||
| Q2 25 | — | $131.0M | ||
| Q1 25 | — | $-232.0M | ||
| Q4 24 | — | $446.0M | ||
| Q3 24 | — | $545.0M | ||
| Q2 24 | — | $6.0M |
自由现金流率ALKTEVA
| Q1 26 | — | — | ||
| Q4 25 | — | 21.6% | ||
| Q3 25 | — | 5.2% | ||
| Q2 25 | — | 3.1% | ||
| Q1 25 | — | -6.0% | ||
| Q4 24 | — | 10.5% | ||
| Q3 24 | — | 12.6% | ||
| Q2 24 | — | 0.1% |
资本支出强度ALKTEVA
| Q1 26 | 10.2% | — | ||
| Q4 25 | — | 3.0% | ||
| Q3 25 | — | 3.0% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 3.3% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | — | 2.3% |
现金转化率ALKTEVA
| Q1 26 | — | — | ||
| Q4 25 | 8.81× | 2.41× | ||
| Q3 25 | 3.14× | 0.85× | ||
| Q2 25 | 2.19× | 0.80× | ||
| Q1 25 | — | -0.49× | ||
| Q4 24 | 3.86× | — | ||
| Q3 24 | 1.35× | — | ||
| Q2 24 | 2.64× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ALK
| Passenger revenue | $2.9B | 88% |
| Loyalty program other revenue | $227.0M | 7% |
| Cargo and other revenue | $153.0M | 5% |
TEVA
| Other | $2.0B | 42% |
| Generics Medicians Including Otc And Biosimilars | $672.0M | 14% |
| Other Products | $608.0M | 13% |
| License | $529.0M | 11% |
| Distribution Service | $366.0M | 8% |
| Other Activities | $227.0M | 5% |
| Ajovy | $106.0M | 2% |
| COPAXONE | $77.0M | 2% |
| Respiratory Product | $65.0M | 1% |
| Uzedy | $55.0M | 1% |
| Bendeka And Treanda | $36.0M | 1% |
